详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Phase II clinical study evaluating the efficacy and safety of disitamab vedotin combined with sintilimab and S-1 in the conversion treatment of HER2-overexpression unresectable gastric cancer

文献详情

资源类型：

WOS体系：

收录情况： ◇ SCIE ◇ CPCI(ISTP)

作者：

机构： [1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [2]Department of Gastric Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [3]Shandong Provincial Hospital, Jinan, China [4]Sichuan Cancer Hospital, Chengdu, Sichuan, China [5]Department of Gastric Surgery, Zhejiang Cancer Hospital, Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China [6]Department of Gastrointestinal Surgery, Peking University Cancer Hospital and Institute, Beijing, China [7]Chinese PLA General Hospital, Beijing, Beijing, China [8]Liaoning Provincial Tumor Hospital, Shenyang, China [9]Department of General Surgery & Guangdong Provincial Key Laboratory of Precision Medicine for Gastrointestinal Tumor, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China [10]Department of Digestive Surgery, Xijing Hospital, Air Force Medical University, Xi'an, Shannxi, China [11]Shanghai Jiaotong University School of Medicine, Renji Hospital, Shanghai, China [12]Department of Pancreatic and Gastric Surgery, National Cancer Center/ National Clinical Research Center for Cancer/ Cancer Hospital, Chinese Academy of Medical, Beijing, China [13]The Third Department of Surgery, the Fourth Hospital of Hebei Medical University, Shijiazhuang, China [14]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China [15]Xiangya Hospital, Central South University, Changsha, Hunan, China [16]Lanzhou University Second Hospital, Lanzhou, China [17]Renmin Hospital of Wuhan University, Wuhan, China

出处：

DOI：

ISSN：

关键词： 281-270-434-6184 281-318-430 281-270-2686-7624 283-424-6846-174 283-424-6846-5514 613-135-244-3829-325 4 3 2 2444 4288

语种：

WOS：

中科院(CAS)分区：

出版当年[2024]版：

无

最新[2023]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2024]版：

无

最新[2023]版：

Q1 ONCOLOGY

影响因子： 42.1 最新[2023版] 37.4 最新五年平均 42.1 出版当年[2023版] 0 出版当年五年平均 42.1 出版前一年[2023版]

第一作者：

第一作者机构： [1]Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Discovery of 4-((3 ' R,4 ' S,5 ' R)-6 ''-Chloro-4 '-(3-chloro-2-fluorophenyl)-1 '-ethyl-2 ''-oxodispiro[cyclohexane-1,2 '-pyrrolidine-3 ',3 ''-indoline]-5 '-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG-115): A Potent and Orally Active Murine Double Minute 2 (MDM2) Inhibitor in Clinical Development [2]KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation [3]Ultrasound-guided microwave ablation for giant breast leiomyoma: A case report [4]Synthesis, in vitro and in vivo evaluation of novel substituted N-(4-(2-(4-benzylpiperazin-1-yl)ethoxy)phenyl)-N-methyl-quinazolin-4-amines as potent antitumor agents. [5]First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study [6]Pecanex functions as a competitive endogenous RNA of S-phase kinase associated protein 2 in lung cancer [7]Unveiling prognosis and traits of dMMR/MSI-H gastric and colorectal cancer after curative surgery: A large-scale, multi-center, retrospective study in China [8]Synthesis and biological evaluation of 1, 2, 4-oxadiazole derivatives as novel GPR119 agonists. [9]First-line serplulimab plus HLX04 and XELOX versus placebo plus bevacizumab and XELOX in metastatic colorectal cancer: A phase 2/3 study [10]Identification and optimization of 3-bromo-N'-(4-hydroxybenzylidene)-4-methylbenzohydrazide derivatives as mTOR inhibitors that induce autophagic cell death and apoptosis in triple-negative breast cancer.